Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Quality-by-design-based development of rivaroxaban-loaded liquisolid compact tablets with improved biopharmaceutical attributes
Rivaroxaban (RXN) finds use in the management of pulmonary embolism and deep vein
thrombosis. Its poor solubility (5–7 µg/mL) and P-gp-mediated efflux from intestinal lining …
thrombosis. Its poor solubility (5–7 µg/mL) and P-gp-mediated efflux from intestinal lining …
Discerning computational, in vitro and in vivo investigations of self-assembling empagliflozin polymeric micelles in type-2 diabetes
P Wagh, S Savaliya, B Joshi, B Vyas… - Drug Delivery and …, 2024 - Springer
Background Empagliflozin (EMPA) is an SGLT2 inhibitor, a new class of anti-diabetic
medication, indicated for treating type-2 diabetes. Its low permeability, poor solubility and …
medication, indicated for treating type-2 diabetes. Its low permeability, poor solubility and …
A Review on Different Solubility Enhancement Techniques of Ticagrelor.
A Srivastava, MA Khan, S Bedi… - International Journal of …, 2023 - search.ebscohost.com
Ticagrelor is a BCS class IV drug that inhibits platelet action by reversibly binding to the
P2Y12 receptor. One of the major challenges faced by the class IV (low solubility, low …
P2Y12 receptor. One of the major challenges faced by the class IV (low solubility, low …
Amalgamation of solid dispersion and melt adsorption techniques for augmentation of oral bioavailability of novel anticoagulant rivaroxaban
The objective of the present study was to evaluate the potential of solid dispersion adsorbate
(SDA) to improve the solubility and bioavailability of rivaroxaban (RXN). SDA of RXN was …
(SDA) to improve the solubility and bioavailability of rivaroxaban (RXN). SDA of RXN was …
[HTML][HTML] Bioanalytical method development, in-vivo pharmacokinetic evaluation, ex-vivo platelet aggregation inhibition activity of a novel solid dispersion formulation of …
A Srivastava, S Bedi, AK Mehata… - Frontiers in Medical …, 2025 - pmc.ncbi.nlm.nih.gov
Background Ticagrelor, a potential antithrombotic drug indicated for cardiovascular events
with acute coronary syndrome, has been restricted from its oral use due to poor aqueous …
with acute coronary syndrome, has been restricted from its oral use due to poor aqueous …
Amalgam of ternary solid dispersion and P-gp efflux inhibition in development of colon-targeted tablets of rifaximin
MS Lalan, PJ Shah, R Kadam… - Journal of Reports in …, 2022 - journals.lww.com
Background: Rifaximin, a BCS class IV drug, possesses low bioavailability due to low
solubility and low permeability attributable to P-gp efflux. The studies attempted to develop …
solubility and low permeability attributable to P-gp efflux. The studies attempted to develop …
[PDF][PDF] Design, optimization, and characterization of a novel amorphous solid dispersion formulation for enhancement of solubility and dissolution of ticagrelor
A SRIVASTAVA, MA KHAN, S BEDI, U Bhandari - Int J App Pharm, 2023 - academia.edu
DESIGN, OPTIMIZATION, AND CHARACTERIZATION OF A NOVEL AMORPHOUS SOLID
DISPERSION FORMULATION FOR ENHANCEMENT OF SOLUBILITY AND D Page 1 DESIGN …
DISPERSION FORMULATION FOR ENHANCEMENT OF SOLUBILITY AND D Page 1 DESIGN …
Fabrication of ticagrelor bioadhesive solid dispersion based on coaxial electrostatic spray to improve drug release and enhance oral bioavailability.
H Liu, H Zhang, C Gu, X Chen, Y Feng… - Pakistan Journal of …, 2023 - search.ebscohost.com
Due to the low solubility and poor bioavailability of Ticagrelor (TIC), the current study
developed a structured bioadhesive core-shell drug delivery system to address it. Ticagreior …
developed a structured bioadhesive core-shell drug delivery system to address it. Ticagreior …